Company Quick10K Filing
Advanzeon
10-K 2019-12-31 Filed 2020-04-09
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-01
10-Q 2019-03-31 Filed 2019-06-14
10-K 2018-12-31 Filed 2019-05-24
10-Q 2018-09-30 Filed 2019-04-24
10-Q 2018-06-30 Filed 2019-04-23
10-Q 2018-03-31 Filed 2019-04-12
10-K 2017-12-31 Filed 2019-01-29
10-K 2014-12-31 Filed 2018-05-18
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-20
10-K 2012-12-31 Filed 2013-04-12
10-Q 2012-09-30 Filed 2012-11-14
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-21
10-K 2011-12-31 Filed 2012-03-30
10-Q 2011-09-30 Filed 2011-11-18
10-Q 2011-06-30 Filed 2011-08-12
10-Q 2011-03-31 Filed 2011-05-16
10-K 2010-12-31 Filed 2011-03-31
10-Q 2010-09-30 Filed 2010-11-15
10-Q 2010-06-30 Filed 2010-08-16
10-Q 2010-03-31 Filed 2010-05-14
10-K 2009-12-31 Filed 2010-04-15
8-K 2020-04-23 Enter Agreement, Off-BS Arrangement
8-K 2019-09-17 Sale of Shares
8-K 2019-05-28 Officers
8-K 2018-09-14 Enter Agreement, Exhibits
8-K 2018-06-01
8-K 2018-05-14 Exhibits
8-K 2018-04-27 Exhibits
8-K 2017-12-31 Enter Agreement, Exhibits
8-K 2015-05-12

Advanzeon Financials

CHCR Metrics, Comps, Filings

Quarterly | Annual

Business

Established in 1969, Advanzeon Solutions, Inc., (formerly Comprehensive Care Corp.) (“Advanzeon”, “we”, “Parent”, or the “Company”), through its wholly-owned subsidiary Pharmacy Value Management Solutions, Inc., (“PVMS”) and its wholly-owned subsidiaries during 2015, and partly in 2016, provided managed care services by acting as the administrator for certain administrative service agreements in the behavioral health and substance abuse fields. We primarily offered these services to commercial, Medicare, Medicaid, Children's Health Insurance Program (“CHIP”) health plans, as well as self-insured companies. Our managed care operations consisted solely of servicing administrative service agreements. Starting in July of 2015, we implemented our comprehensive sleep apnea program, called “SleepMaster Solutions” ™. SleepMaster Solutions (“SMS”) utilizes an administrative system for the convenient identification/testing and therapy of Obstructive Sleep Apnea (“OSA”). We partnered with a national health care provider by initiating a sleep apnea wellness program whereby we screened, tested and when needed, offered a treatment programs for treating this disorder. We also contracted with a union to treat its driver members. Beginning in 2017, our only business was our SMS sleep apnea program.

In 2014, the Department of Transportation (“DOT”) overhauled its system such that regulations now require commercial drivers, that is drivers with a commercial driver's license (‘CDL”) must be specifically examined with respect to whether or not they have a respiratory dysfunction which is defined to include Obstructive Sleep Apnea (“OSA”). OSA is a breathing disorder that causes the airway in a person's throat to close during sleep for ten seconds or more. This loss of breathing function can occur as many as 400 times during the night, and those who have the disorder wake up multiple times, which can lead to exhaustion during the day. Although OSA is diagnosed across a wide demographic, there are certain factors that increase the risk of a person developing this disorder:

The troubling aspect of OSA as it relates to CDL drivers is that it causes intense fatigue often causing a driver to struggle with focusing and remaining alert while driving. Sleep apnea is one of the major contributing factors in truck accidents.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
JetPay (JTPY) 28,637 41% 6.8 -1% 171,416 107,921 66,457 26,994 -1,047 4,875 33,287
Zivo Bioscience (ZIVO) 28,620 -3.9 -10,555% 70 10,973 0 0 -7,378 -7,378 28,605
Pivot Pharmaceuticals (PVOTF) 28,605 -4.6 -70% 9,549 6,181 0 0 -6,666 -6,195 28,560
Jones Soda (JSDA) 28,533 21% -10.6 -24% 11,202 3,488 11,685 2,432 -2,670 -2,025 21,562
General Cannabis (CANN) 28,438 73% -3.3 -210% 4,611 5,703 4,225 3,065 -9,663 -9,239 30,057
Investview (INVU) 28,403 95% -3.1 -74% 12,478 16,067 22,487 21,461 -9,179 -8,893 27,145
Cannabics Pharmaceuticals (CNBX) 27,044 31% 14.8 9% 19,772 454 11 3 1,794 1,794 26,551
United Cannabis (CNAB) 28,154 4% -1.6 -193% 9,051 14,945 13,098 487 -17,423 -16,727 27,588
Q Biomed (QBIO) 27,006 -4.5 -1,090% 682 5,043 0 0 -7,437 -6,777 30,497
Advanzeon (CHCR) 27,618 70% -14.6 -100% 2,742 30,704 301 210 -2,746 -2,746 40,162
Jerrick Media Holdings (JMDA) 27,492 100% -5.4 -192% 2,815 8,728 133 133 -5,404 -5,075 27,325
Target Group (CBDY) 27,351 -6.5 -20% 21,149 6,521 0 0 -4,306 -4,212 27,259
Provectus Biopharmaceuticals (PVCT) 27,200 -6.6 -343% 1,564 24,152 0 0 -5,367 -4,066 26,766
Neuroone Medical Technologies (NMTC) 27,122 -4.0 -1,273% 533 1,770 0 0 -6,781 -6,764 26,862
Peerstream (PEER) 27,093 80% -1,005.5 -2% 19,727 3,788 12,704 10,180 -484 -23 23,468
Social Life Network (WDLF) 27,065 -4% -7.4 367,804,900% 814 177 -8 -3,678 -3,677 27,048
Know Labs (KNWN) 26,998 22% -9.9 -272% 2,640 5,937 2,303 514 -7,187 -3,196 31,595
Cannabis Sativa (CBDS) 26,935 57% -15.1 -50% 4,419 2,819 813 467 -2,228 -1,770 26,713
Innovation Pharmaceuticals (IPIX) 26,737 -3.3 -190% 4,315 8,859 0 0 -8,181 -7,945 25,827
Quaint Oak Bancorp (QNTO) 26,452 3.1 1% 293,820 268,272 0 0 1,880 6,849 20,946

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302014-12-312017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash1,2906488321,1731,4911,5899201,7631,24512181307225152164
Accounts Receivable11478344941,2041,3144,5461,336850271147473525222825
Inventory
PP&E6145473923232652122,17713210733611100222
Assets15,14714,67815,31615,02616,02115,9746,1243,7483,071408831564938728791,1101,6482,742
Accounts Payable1,6581,3231,1901,1761,0811,1101,1971,0015439474006629087009181,0991,423
Long-Term Debt4,5806,3706,5621,7321,4782494,75203,9309,82810,26610,82511,10111,70812,608
Liabilities25,09826,41531,79831,27730,56729,35029,06727,85228,30817,44331,10731,95225,07626,11926,78227,71028,86330,704
Stockholders' Equity-9,951-11,737-16,482-16,251-14,546-13,376-22,943-24,104-25,237-17,035-31,024-31,797-24,583-25,248-25,903-26,600-27,215-27,963
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302014-12-312017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue18,55717,20017,1711812839975689068
Cost of Revenue18,79417,12118,81316,64413,76513,06011,3717896824918546-1942662
Gross Profit-23779-1,642132975394262466
R&D
SG&A2,8962,1825,1695152,2262,0431,9861,3911,488474513409349426432428
Tax36-1148321293320000000
Net Income-3,970-2,550-7,609804,2371,037-9,714-1,407-1,647-1,0126,878-656-728-615-748
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302014-12-312017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-2,883-1,674378434178-6381,299-1,255-255-482-659-366-722-962
Cash Investing-13-4-1-200
Cash Financing2,2541,862-36-115-80-30-4567372506123587271,005